Furthermore, the CRISPR‐mediated liver cancer model in our study was induced by PTEN and TP53 mutations, which are predictors of a poor response to targeted therapy and immunotherapy and also predictors of poor survival.[20, 21, 22, 23] Thus, our cynomolgus monkey model simulated patients with refractory liver cancer, and the potent in vivo efficiency of Mehozumab‐DM1 suggests that it is a promising clinical treatment for refractory HCC. This evidence concerns the gene PTEN and liver cancer.